On Invalid Date, Supernus Pharmaceuticals (NASDAQ: SUPN) reported Q4 2023 earnings per share (EPS) of $0.02, up 95.74% year over year. Total Supernus Pharmaceuticals earnings for the quarter were $1.18 million. In the same quarter last year, Supernus Pharmaceuticals's earnings per share (EPS) was $0.47.
As of Q2 2024, Supernus Pharmaceuticals's earnings has grown -98.23% year over year. This is 111.11 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry earnings growth rate of 12.88%. Supernus Pharmaceuticals's earnings in the past year totalled $1.32 million.
What is SUPN's earnings date?
Supernus Pharmaceuticals's earnings date is Invalid Date. Add SUPN to your watchlist to be reminded of SUPN's next earnings announcement.
What was SUPN's revenue last quarter?
On Invalid Date, Supernus Pharmaceuticals (NASDAQ: SUPN) reported Q4 2023 revenue of $164.31 million up 1.8% year over year. In the same quarter last year, Supernus Pharmaceuticals's revenue was $167.33 million.
What was SUPN's revenue growth in the past year?
As of Q2 2024, Supernus Pharmaceuticals's revenue has grown -8.95% year over year. This is 18.93 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 9.98%. Supernus Pharmaceuticals's revenue in the past year totalled $607.52 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.